AbCellera Biologics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	79.21	75.13	28.83	38.03	485.42	375.2
Revenue Growth (YoY)	242.66%	160.56%	-24.17%	-92.17%	29.38%	60.92%
Gross Profit	79.21	75.13	28.83	38.03	485.42	375.2
Selling, General & Admin	59.28	83.23	85.49	75.18	66.76	48.76
Depreciation & Amortization Expenses	23.68	22.17	90.85	24.4	27.84	14.45
Research & Development	191	186.83	167.26	175.66	107.88	62.06
Other Operating Expenses	-	-	-	-	66.44	45.52
Total Operating Expenses	273.95	292.23	343.6	275.23	268.91	170.79
Operating Income	-183.38	-217.1	-314.77	-237.21	216.51	204.41
Interest Income	20.28	28.33	38.47	42.25	16.08	3.33
Other Non-Operating Income (Expense)	10.25	11.18	75.9	20.93	6.51	11.41
Total Non-Operating Income (Expense)	30.53	39.51	114.37	63.18	22.59	14.74
Pretax Income	-154.65	-177.6	-200.4	-174.03	239.1	219.15
Provision for Income Taxes	-19.64	-31.18	-37.54	-27.63	80.58	65.69
Net Income	-135.01	-146.41	-162.86	-146.4	158.52	153.46
Net Income to Common	-135.01	-146.41	-162.86	-146.4	158.52	153.46
Net Income Growth	-	-	-	-	3.29%	29.05%
Shares Outstanding (Basic)	300	299	294	289	285	276
Shares Outstanding (Diluted)	300	299	294	289	315	318
Shares Change (YoY)	1.52%	1.49%	1.79%	-8.15%	-1.09%	20.96%
EPS (Basic)	-0.48	-0.49	-0.55	-0.51	0.56	0.56
EPS (Diluted)	-0.48	-0.49	-0.55	-0.51	0.50	0.48
EPS Growth	-	-	-	-	4.17%	6.67%
Shares Outstanding	303.95	300.6	295.76	290.83	286.85	283.26
Free Cash Flow	-189.23	-174.07	-186.95	-120.82	206.7	186.13
Free Cash Flow Growth	-	-	-	-	11.05%	1329.91%
Free Cash Flow Per Share	-0.63	-0.58	-0.64	-0.42	0.66	0.58
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-231.52%	-288.98%	-1091.69%	-623.82%	44.60%	54.48%
Profit Margin	-170.45%	-194.88%	-564.83%	-385.00%	32.66%	40.90%
FCF Margin	-238.91%	-231.69%	-648.40%	-317.75%	42.58%	49.61%
EBITDA	-152.51	-188.28	-217.77	-206.31	249.61	221.66
EBITDA Margin	-192.55%	-250.61%	-755.27%	-542.57%	51.42%	59.08%
EBIT	-183.38	-217.1	-314.77	-237.21	216.51	204.41
EBIT Margin	-231.52%	-288.98%	-1091.69%	-623.82%	44.60%	54.48%
Effective Tax Rate	12.70%	17.56%	18.73%	15.88%	33.70%	29.97%

Updated May 11, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q